Sargent Bickham Lagudis’s Lyell Immunopharma LYEL Stock Holding History

Sargent Bickham Lagudis’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$3.47K	Buy	+50	New	+$4.97K	﹤0.01%	846

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sargent Bickham Lagudis's LYEL Position: Q4 2022 in Review

Sargent Bickham Lagudis opened a new position in Lyell Immunopharma (LYEL) in Q4 2022: 50 shares worth $3.47K. The stake represents ﹤0.01% of the portfolio and ranks #846 among its holdings.

93 funds tracked by Wall St. Rank hold LYEL as of Q4 2022.

Sargent Bickham Lagudis held 50 shares of Lyell Immunopharma worth $3.47K as of Q4 2022.
Lyell Immunopharma was a new Sargent Bickham Lagudis position in Q4 2022.
Lyell Immunopharma made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #846 holding.
93 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.